Literature DB >> 10888878

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase.

H Shimura1, N Hattori, S i Kubo, Y Mizuno, S Asakawa, S Minoshima, N Shimizu, K Iwai, T Chiba, K Tanaka, T Suzuki.   

Abstract

Autosomal recessive juvenile parkinsonism (AR-JP), one of the most common familial forms of Parkinson disease, is characterized by selective dopaminergic neural cell death and the absence of the Lewy body, a cytoplasmic inclusion body consisting of aggregates of abnormally accumulated proteins. We previously cloned PARK2, mutations of which cause AR-JP (ref. 2), but the function of the gene product, parkin, remains unknown. We report here that parkin is involved in protein degradation as a ubiquitin-protein ligase collaborating with the ubiquitin-conjugating enzyme UbcH7, and that mutant parkins from AR-JP patients show loss of the ubiquitin-protein ligase activity. Our findings indicate that accumulation of proteins that have yet to be identified causes a selective neural cell death without formation of Lewy bodies. Our findings should enhance the exploration of the molecular mechanisms of neurodegeneration in Parkinson disease as well as in other neurodegenerative diseases that are characterized by involvement of abnormal protein ubiquitination, including Alzheimer disease, other tauopathies, CAG triplet repeat disorders and amyotrophic lateral sclerosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10888878     DOI: 10.1038/77060

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  583 in total

1.  Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.

Authors:  L Stefanis; K E Larsen; H J Rideout; D Sulzer; L A Greene
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

Review 2.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  DJ-1 is critical for mitochondrial function and rescues PINK1 loss of function.

Authors:  Ling-Yang Hao; Benoit I Giasson; Nancy M Bonini
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

Review 4.  Recent advances in the genetics of Parkinson's disease.

Authors:  Ian Martin; Valina L Dawson; Ted M Dawson
Journal:  Annu Rev Genomics Hum Genet       Date:  2011       Impact factor: 8.929

Review 5.  Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.

Authors:  Fernanda Martins Lopes; Ivi Juliana Bristot; Leonardo Lisbôa da Motta; Richard B Parsons; Fabio Klamt
Journal:  Neuromolecular Med       Date:  2017-07-18       Impact factor: 3.843

Review 6.  Programmed cell death and new discoveries in the genetics of parkinsonism.

Authors:  Robert E Burke
Journal:  J Neurochem       Date:  2007-12-10       Impact factor: 5.372

7.  Parkin Regulates Mitosis and Genomic Stability through Cdc20/Cdh1.

Authors:  Seung Baek Lee; Jung Jin Kim; Hyun-Ja Nam; Bowen Gao; Ping Yin; Bo Qin; Sang-Yeop Yi; Hyoungjun Ham; Debra Evans; Sun-Hyun Kim; Jun Zhang; Min Deng; Tongzheng Liu; Haoxing Zhang; Daniel D Billadeau; Liewei Wang; Emilie Giaime; Jie Shen; Yuan-Ping Pang; Jin Jen; Jan M van Deursen; Zhenkun Lou
Journal:  Mol Cell       Date:  2015-09-17       Impact factor: 17.970

Review 8.  The genetics of Parkinson's disease.

Authors:  Kah Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 9.  Structural and functional insights to ubiquitin-like protein conjugation.

Authors:  Frederick C Streich; Christopher D Lima
Journal:  Annu Rev Biophys       Date:  2014       Impact factor: 12.981

10.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants.

Authors:  Jessica C Greene; Alexander J Whitworth; Isabella Kuo; Laurie A Andrews; Mel B Feany; Leo J Pallanck
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.